ESUR prostate MR guidelines 2012
- First Online:
- Cite this article as:
- Barentsz, J.O., Richenberg, J., Clements, R. et al. Eur Radiol (2012) 22: 746. doi:10.1007/s00330-011-2377-y
- 14k Views
The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by “minimal” and “optimal” requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for “detection”, “staging” and “node and bone” are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented.
• This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer.
• Clinical indications, and minimal and optimal imaging acquisition protocols are provided.
• A structured reporting system (PI-RADS) is described.
In their lifetime, 1 in 6 men will be clinically diagnosed with prostate cancer. This accounts for annually 350,000 cases, which is 25% of all new male malignancies diagnosed in Europe [1–4]. Currently, digital rectal examination (DRE), serum prostate specific antigen (PSA)—a non-specific blood test—and trans-rectal ultrasound (TRUS) guided biopsy—where the target is mostly invisible—are used as diagnostic tools. Advances in MRI show promise for improved detection and characterisation of prostate cancer, using a multi-parametric approach, which combines anatomical and functional data. Thus far optimal acquisition and evaluation have not been agreed , and as is often the case in clinical practice, it is not satisfactory to await conclusions from large scale imaging and oncological trials. As a first step, the European Society of Urogenital Radiology (ESUR) has called upon Europe-wide expertise to produce a set of guidelines on MRI on prostate cancer.
An ESUR working group of prostate MRI experts had informal discussions at international congresses and by e-mail. This crystallised into a series of specialist sub-groups. The criteria for group inclusion were radiologists with at least 3 years of experience in prostate MRI (>50/year), conducting research comparing image results with pathological specimens, co-working with urologists, and producing peer reviewed international articles. Over a 21/2-year period five meetings took place. Based on the recommendations of the sub-group chairs a consensus document was established and finalised by two consensus meetings and e-mail discussion.
Section 1: clinical use of MRI
Recommended use of MRI in prostate cancer consists of multi-parametric (mp-MRI). This includes a combination of high-resolution T2-weighted images (T2WI), and at least two functional MRI techniques, as these provide better characterisation than T2WI with only one functional technique [6–9]. Within an mp-MRI examination, the relative clinical value of its component techniques differs. In addition to T2WI MRI, which mainly assesses anatomy, diffusion weighted imaging (DWI) [10–15] and MR spectroscopic imaging (MRSI) [16, 17] add specificity to lesion characterisation, while dynamic contrast enhanced MRI (DCE-MRI) has a high sensitivity in cancer detection [9, 18, 19].
Clinical use of MRI
If PSA is elevated (>3–4 ng/mL) or DRE indicates suspected tumour, TRUS-guided biopsy will be performed to detect potential cancer, and assess its extent, volume and aggression. But, PSA has low specificity (36%), thus increased PSA is not equivalent with tumour. Also, normal PSA does not exclude tumour. Finally, TRUS biopsy underestimates the extent and grade of prostate cancer.
Low-risk: PSA <10 ng/mL, and biopsy Gleason score ≤6, and clinical stage T1–T2a
Intermediate-risk: PSA 10–20 ng/mL, or biopsy Gleason score 7, or clinical stage T2b or T2c
High-risk: PSA >20 ng/mL, or Gleason score 8–10, or clinical stage >T2c.
Treatment options: role of MRI
Treatment options: role of MRI
10–15 year estimated life expectancy (Generally these patients will be younger than 75)
Yes—consider nerve sparing
External or brachytherapy
Less than 10–15 years
External or brachytherapy
In combination with hormones
Treatment intention is radical surgery, radiotherapy or active surveillance (AS). Mp-MRI can be helpful in managing low risk patients and guide them towards AS, by confirming the absence of significant intra-prostatic disease. Additionally, mp-MRI can be used to help nerve and continence sparing surgery, and to focus radiotherapy.
Acquisition protocols: minimum requirements
A. Detection protocol
Fast <30-min protocol without an endorectal coil (ERC). Images should cover entire prostate, and include T2WI, DWI and DCE-MRI. Imaging can adequately be performed at 1.5 T using a good 8- to 16-channel pelvic phased array (PPA). Anti-peristaltic drugs (Buscopan®, Glucagon®) should be given.
• T2WI axial+sagittal: 4 mm at 1.5 T, 3 mm at 3 T; in plane resolution: 0.5 × 0.5 mm to 0.7 × 0.7 mm at both 1.5 T and 3 T.
• DWI axial: 5 mm at 1.5 T, 4 mm at 3 T; in-plane resolution: 1.5 × 1.5 mm to 2.0 × 2.0 mm at 1.5 T and 1.0 × 1.0 mm to 1.5 × 1.5 mm at 3 T. ADC map should be calculated. At least 3 b-values should be acquired in three orthogonal directions and adapted to quality of SNR: 0, 100 and 800–1000 s/mm2. For calculation of ADC, the highest b-value that should be used is 1000 s/mm2.
• DCE-MRI axial: 4 mm at 1.5 T and 3 T; in plane resolution: 1.0 × 1.0 mm at 1.5 T and 0.7 × 0.7 mm at 3 T. Quantitative or semi-quantitative DCE-MRI analysis does not have to be performed. Maximum temporal resolution should be 15 s following single dose of contrast agent with an injection rate of 3 mL/s. For DCE-MRI, imaging acquisition should be continued for 5 min to detect washout. Unenhanced T1WI images from this sequence can be used to detect post-biopsy haematomas.
• MRSI: optionally, MRSI can be added to the detection protocol, but this requires an extra 10–15 min of examination time. For this ERC is mandatory at 1.5 T and optional at 3 T; volume of interest (VOI) aligned to axial T2WI; coverage of the whole prostate in the VOI; field of view at least 1.5 voxels larger than the VOI in all directions to avoid wrap-around or back folding; matrix of at least 8 x 8 x 8 phase-encoding steps with nominal voxel size <0.5 cc; spectral selective suppression of water and lipid signals; positioning of at least six fat saturation bands close to the prostatic margin (may be positioned inside the VOI) to conform to the prostatic shape as closely as possible; automatic or manual shimming up to a line width at half height of the water resonance peak between 15 and 20 Hz at 1.5 T and between 20 and 25 Hz at 3 T.
B. Staging protocol
45-min protocol for evaluating minimal extra-capsular extension. Preferably, this examination should be done with an ERC. Images should include entire prostate, with anti-peristaltic drugs.
• T2WI axial, coronal and sagittal planes, 3 mm at 1.5 T and 3 T; in plane resolution: 0.3 × 0.3 mm to 0.7 × 0.7 mm at 1.5 T and 0.3 × 0.3 mm to 0.5 × 0.5 mm at 3 T.
• DWI and DCE as detection protocol.
• MRSI optional.
C. Nodes and bone protocol
30-min protocol, to assess nodal size and bone marrow metastases. Should be performed separately from A and B, as most patients do not require bone or node staging.
• T1WI coronal of lower lumbar spine plus pelvis (SE or f/T SE) 3.0-mm slices
• 3D f/T SE T2WI coronal of lower lumbar spine plus pelvis; 1.0-mm isometric voxels
• DWI coronal of lower lumbar spine plus pelvis (b-values 0 and 600); slice thickness 3–4 mm, in plane resolution: 2.5–3.0 mm voxels
• T1WI sagittal cervical and thoracic spine (SE or f/T SE)
• STIR or DWI sagittal cervical and thoracic spine.
In high risk patients, bone scintigraphy or MRI to detect skeletal or nodal metastases is recommended. Here the “node and bone protocol” is advised (see Table 2C). If information is required about the local stage, the “staging protocol” may additionally be performed.
Lymph node staging of prostate cancer using conventional MRI is unreliable, as 70% of metastatic lymph nodes in prostate cancer are often small (<8 mm). If however, the a priori risk of having nodal metastases is >40%, MRI or CT should be performed . Urologists use a lower a priori threshold of 10–17% to perform pelvic lymph node dissection .
MRI to determine tumour aggression
Mp-MRI techniques give increased conspicuity of tumour detection within the prostate and highlight areas of more aggressive disease within a short examination time (“detection protocol”, Table 2A). The prediction of the Gleason score is better assessed by DWI and 1H-MRSI compared with T2WI and DCE-MRI .
PSA testing—every 3 months for 2 years, then every 6 months
Repeat prostate TRUS-guided biopsies every 2–3 years.
Mp-MRI before AS is advocated, as it allows detection of adverse prognostic features such as tumour volume, and higher grade tumours, particularly in the anterior and apical lesions. DCE-MRI and DWI plus T2WI are highly accurate in detecting tumours >0.5 cc volume [18, 28]. Furthermore, MRSI plus T2WI have been reported to be very helpful in both excluding and detecting high-grade cancers >0.5 cc (sensitivity 93%, NPV 98%) [29, 30]. The results of mp-MRI can be used to direct further biopsy for more accurate grading of the tumour.
Mp-MRI in men suspected to have prostate cancer with negative previous TRUS biopsy
Investigating men post-therapy with PSA rise
Mp-MRI can be considered to be a tool to evaluate the prostatic fossa in patients with low PSA recurrence (values ranged between 0.2–2 ng/mL) where according to the EAU, other techniques (PET, TRUS biopsy) are not recommended . When curative aggressive treatment (e.g. salvage radiotherapy) is considered, in addition to T2WI, DCE-MRI and DWI should always be performed using the “detection protocol” [36–39]. Nodes and bone can be evaluated with the “node and bone” protocol.
Section 2: MRI sequences for prostate gland evaluation
T2-weighted MR imaging
T2-weighted imaging (T2WI) provides the best depiction of the prostate’s zonal anatomy and capsule. T2WI is used for prostate cancer detection, localisation and staging. T2WI alone is not recommended because additional functional techniques improve both sensitivity and specificity. T2WI are obtained in 2–3 planes. The axial T2WI sequence must cover the entire prostate and seminal vesicles, and are orthogonal to the rectum. The phase encoding direction is left-to-right so that motion artefact does not overlap the prostate. Bowel motion artefacts should be reduced by administering an anti-peristaltic agent. The patient should be instructed about the importance of not moving during image acquisition. An endorectal coil (ERC) is not an absolute requirement at either 1.5 T or 3 T, but a pelvic phased array (PPA) coil with a minimum of 16 channels is required.
The interpretation of T2WI includes evaluation of the capsule, seminal vesicles and posterior bladder wall for extra-prostatic tumour invasion. Criteria for extra-capsular extension are abutment; irregularity and neurovascular bundle thickening; bulge, loss of capsule and capsular enhancement; measurable extra-capsular disease; obliteration of the recto-prostatic angle. For seminal vesicle infiltration the criteria are: expansion; low T2 signal intensity; filling in of the prostate–seminal vesicle angle; enhancement and impeded diffusion (see Table 4).
Caveats and conclusions
T2WI alone is sensitive but not specific for prostate cancer and should be improved using two functional techniques.
Lesion detection is particularly problematic in the TZ because benign prostatic hyperplasia (BPH) looks like cancer . However, presence of an “erased charcoal sign” in a lenticular lesion is highly suggestive of cancer.
Biopsy-related haemorrhage can cause artefacts that mimic cancer and limit lesion localisation and staging. To prevent this, the time interval between the biopsy procedure and MRI should be at least 4–6 weeks  and preliminary T1WI can be done to exclude biopsy-related haemorrhage. If significant haemorrhage is seen, the patient can be rescheduled 3–4 weeks later to allow resolution of the haemorrhage.
Dynamic contrast enhanced MRI
Dynamic contrast enhanced (DCE) MRI following the administration of gadolinium-based contrast medium is the most common imaging method for evaluating tumour vascularity . As normal prostate is also highly vascular, a comparison of pre- and post-gadolinium images is usually insufficient to discern prostate cancer [44, 45]. A fast and direct method of characterising prostatic vascular pharmacokinetic features is high temporal resolution DCE-MRI (<10 s). DCE-MRI consists of a series of axial T1WI gradient echo sequences covering the entire prostate during and after IV bolus injection (2–4 mL/s) of gadolinium-based contrast medium [46, 47]. T1WI DCE-MRI imaging data can be assessed in three ways: qualitatively, semi-quantitatively or quantitatively.
DCE-MRI for prostate cancer detection, localisation, staging and recurrence detection
Hara et al have shown that DCE-MRI is able to detect clinically important prostate cancer in 93% of cases . In patients with previous negative TRUS-guided biopsy sessions and rising PSA level, DCE-MRI plays an important role in lesion detection (Fig. 3d, e) .
Several studies have found that DCE-MRI is superior to T2WI for prostate cancer localisation.
Although the literature is sparse, available data suggest that DCE may improve staging. Thus, DCE-MRI is essential for the detection of post-prostatectomy [36, 37] and -radiotherapy recurrences [38, 39].
Caveats and conclusions
Dynamic contrast enhanced MRI is a valuable tool for MRI of prostate cancer, improving tumour localisation and local staging. However, it should always be combined with T2WI and DWI, as discrimination among prostatitis, BPH and prostate cancer in the TZ is more challenging with DCE-MRI alone.
Diffusion weighted MRI
Diffusion weighted imaging (DWI) is a powerful clinical tool, as it allows apparent diffusion coefficient (ADC) maps to be calculated, enabling qualitative and quantitative assessment of prostate cancer aggressiveness. Cancer shows a lower ADC value than normal prostate tissue. Furthermore ADC values correlate with Gleason scores [10–15].
Diffusion weighted imaging should be acquired in the axial plane with an echo planar imaging sequence employing parallel imaging. Motion probing gradients should be applied in three orthogonal directions and adapted to the quality of the SNR. The minimal requirements are b-values of 0, 100, and 800–1000 s/mm2. The choice of these values enables calculation of diffusion sensitive ADC values (by excluding the b = 0 data from the ADC calculation). For optimal DWI, the b-values are: 0, 100, 500, and 800–1000 s/mm2. TE should be as short as achievable (typically <90 ms).
Apparent diffusion coefficient maps can be generated from the index DWI data on the MR console itself, and have to be analysed qualitatively and quantitatively.
Prostate cancer demonstrates high signal intensity on DWI at high b-values and low signal intensity/value on ADC maps [50–52]. For qualitative assessment high b-value (800–1000) DW images and ADC maps should be used. These should be evaluated in combination with T2WI for the anatomical detail. However, some normal prostatic tissue, especially in the TZ, may reveal high signal intensity on DWI and low ADC, thus mimicking tumour. This may be overcome by using very high b-values (>1000 s/mm2).
For quantitative assessment ADC values are used. However, there is variability when using different field strengths, different b-values, and different models to fit the data. Also, there is a considerable inter-patient variability. Thus absolute values should be used with care. Until now DWI has not given additional information for staging.
Caveats and conclusions
Diffusion weighted imaging is an essential component of mp-MRI (Fig. 3a–c). It provides information about tumour aggressiveness, and improves specificity in prostate cancer detection compared with T2WI alone. DWI correlates well with tumour volume of the index prostatic lesions. It should, therefore, be part of routine assessments of patients with prostate cancer.
Diffusion weighted imaging is, however, affected by magnetic susceptibility effects resulting in spatial distortion and signal loss. Large b-values are required to suppress normal prostate tissue background signal and ADC maps should be used to minimise T2 shine-through .
MR spectroscopic imaging
Magnetic resonance spectroscopic imaging (MRSI) is able to show the lower levels of citrate and higher levels of choline of prostate cancer compared with benign tissue . MRSI is performed with a 3D chemical shift imaging protocol (details can be found in Appendix 3). The use of an ERC is imperative at 1.5 T, but optional at 3 T. The volume of interest (VOI) is aligned to axial T2WIs to maximise coverage of the whole prostate, while minimising contamination by surrounding tissue. It is partitioned into a matrix of at least 8 × 8 × 8 phase-encoding steps. Applying spectral selective water and lipid suppression close to the prostatic margins reduces unwanted water and lipid signals in the VOI.
After post-processing, using commercially available software packages, spectral information is overlaid on T2WIs.The relevant metabolites are citrate (marker of benign tissue), creatine (insignificant for diagnosis, but difficult to resolve from choline), and choline (marker of malignant tissue). In quantitative analysis, the peak integrals of all metabolites are estimated by means of the choline-plus-creatine-to-citrate (CC/C) ratio. Cancer in PZ and TZ should have in at least two adjacent voxels a CC/C ratio exceeding respectively 2 and 3 standard deviations above the mean ratio [53–57]. In qualitative analysis, the peak heights of citrate and choline are visually compared (Fig. 2b, c) .
Magnetic resonance spectroscopic imaging can be used to predict the presence or absence of cancer [21, 29, 30]. It also provides information about lesion aggressiveness, but does not give staging information owing to its poor spatial resolution. Thus, MRSI is a valid tool for detecting cancer recurrence [59–65] and monitoring therapy response .
Caveats and conclusions
Magnetic resonance spectroscopic imaging provides valuable information about lesion aggression, but requires expertise, use of an endorectal coil at 1.5 T, and adds time to the examination. Whether MRSI is included in the mp-MRI examination depends on personal local experience and availability.
Section 3. MR equipment
The ERC+PPA coil combination provides excellent SNR and remains state-of-the-art for staging prostate cancer. However, it has recognised drawbacks in terms of cost and patient acceptability.
Compare tumour detection/localisation, and staging accuracy of PPA vs. ERC+PPA coil MRI.
Assess the clinical relevance of minimal extra-prostatic disease detected by ERC usage.
Imaging at 3 T
Prostate imaging at 3 T benefits from higher SNR, and enables high quality imaging within a short time without the use of an ERC. Data on 3 T for prostate cancer MRI are still conflicting . Thus further research on this topic is needed
Limitations of 3 T MRI are shorter T2 and longer T1 relaxation times , problems with susceptibility artefacts [69, 70], dielectric effect, specific absorption rate , and the homogeneity of the magnetic field. However, hardware, multi-channel coil, and parallel imaging technique improvements are currently solving most of these problems.
Section 4. Integration, reporting and communication of multi-parametric prostate MRI data
PI-RADS score which relays the probability of cancer risk and its aggression, plotted on a scheme
Location and, probability of extra-prostatic disease
Pertinent incidental findings.
Scoring system for mp-MRI (PI-RADS)
As a minimum requirement division of the prostate 16 regions, as an optimal requirement into 27 regions.
Individual lesions being given a (PI-RADS) score.
Maximum dimension of the largest abnormal lesion.
Score 1 = Clinically significant disease is highly unlikely to be present
Score 2 = Clinically significant cancer is unlikely to be present
Score 3 = Clinically significant cancer is equivocal
Score 4 = Clinically significant cancer is likely to be present
Score 5 = Clinically significant cancer is highly likely to be present.
PI-RADS scoring system
A1. T2WI for the peripheral zone (PZ)
Uniform high signal intensity (SI)
Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated
Intermediate appearances not in categories 1/2 or 4/5
Discrete, homogeneous low signal focus/mass confined to the prostate
Discrete, homogeneous low signal intensity focus with extra-capsular extension/invasive behaviour or mass effect on the capsule (bulging), or broad (>1.5 cm) contact with the surface
A2. T2WI for the transition zone (TZ)
Heterogeneous TZ adenoma with well-defined margins: “organised chaos”
Areas of more homogeneous low SI, however well marginated, originating from the TZ/BPH
Intermediate appearances not in categories 1/2 or 4/5
Areas of more homogeneous low SI, ill defined: “erased charcoal sign”
Same as 4, but involving the anterior fibromuscular stroma or the anterior horn of the PZ, usually lenticular or water-drop shaped.
B. Diffusion weighted imaging (DWI)
No reduction in ADC compared with normal glandular tissue. No increase in SI on any high b-value image (≥b800)
Diffuse, hyper SI on ≥b800 image with low ADC; no focal features, however, linear, triangular or geographical features are allowed
Intermediate appearances not in categories 1/2 or 4/5
Focal area(s) of reduced ADC but iso-intense SI on high b-value images (≥b800)
Focal area/mass of hyper SI on the high b-value images (≥b800) with reduced ADC
C. Dynamic contrast enhanced (DCE)-MRI
Type 1 enhancement curve
Type 2 enhancement curve
Type 3 enhancement curve
For focal enhancing lesion with curve type 2–3
For asymmetric lesion or lesion at an unusual place with curve type 2–3
D2. Qualitative magnetic resonance spectroscopic imaging (MRSI)
Citrate peak height exceeds choline peak height >2 times
Citrate peak height exceeds choline peak height times >1, <2 times
Choline peak height equals citrate peak height
Choline peak height exceeds citrate peak height >1, <2 times
Choline peak height exceeds citrate peak height >2 times
In addition to Table 3, for quantitative analysis of 1.5 T MRSI, the following score can be used:
>4 standard deviations from the mean normal value: 5 points
>3–4 standard deviations from the mean normal value: 4 points
>2–3 standard deviations from the mean normal value: 3 points
>1–2 standard deviations from the mean normal value: 2 points
≤1 standard deviation from the mean normal value: 1 point
Scoring of extra-prostatic disease
Neurovascular bundle thickening
Bulge, loss of capsule
Measurable extra-capsular disease
Low T2 signal
Filling in of angle
Enhancement and impeded diffusion
Effacement of low signal sphincter muscle
Abnormal enhancement extending into sphincter
Loss of low T2 signal in bladder muscle
Abnormal enhancement extending into bladder neck
Conclusion and considerations
These recommendations argue cogently that mp-MRI should be an integral part of prostate cancer diagnosis and treatment. Although disputed by some urologists , the minimal requirements for the acquisition of MR images can be met with the generally available 1.5- and 3-T MR systems.
The authors wish to thank the following members of the ESUR Committee on the Prostate MRI Guidelines: Claire Allen, Michel Claudon, Francois Cornud, Ferdinand Frauscher, Nicolas Grenier, Alex Kirkham, Frederic Lefevre, Gareth Lewis, Ulrich Muller-Lisse, Anwar Padhani, Valeria Panebianco, Pietro Pavlica, Phillipe Puech, Jarle Rorvik, Andrea Rockall, Catherine Roy, Tom Scheenen, Harriet Thoeny, Baris Turkbey, Ahmet Turgut, Derya Yakar.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.